Artemis One Health
Behind the scenes of the many successful projects that Artemis runs there is a managing team like in any other corporation. While the ethos of Artemis is reflected within our corporate governance activities, the details of how the corporation legally works are important to understand.
Artemis One Health Research Foundation (kvk: 32172291) was established on the 11th of May 2010. To realize the objectives of the foundation, the foundation is allowed to outsource work to third parties including Artemis One Health Research Ltd. The private company (kvk: 51502259) was established on 21st of December 2010 for performing research, at a high level, for animal and human health, within Europe. The results of the private company provide no pecuniary reward (non-profit organization) and 100% is put back into the foundation. The foundation is the only shareholder of the private company.
Board of Directors
The Board sets corporate policy, appoints officers, and delegates policy or execution to those officers. The Foundation is governed by a Board of Directors consisting of 2 persons: Guido Maertens, and Linda van de Burgwal. The board of directors of the private company is carried out by the foundation as a legal entity. Through the work of the Board and its Committees, the Board sets policies and strategic direction for the Foundation, approves grant-making areas, fundraising strategies and investments.
The board elects a Chairman, which is the chief financial officer, a director (CEO) and appoints a usual slate of executive officers. Officer positions are all paid, and serve at the direction of the board in their specific areas of responsibility. Officers are responsible both for managing the Foundation affairs in their specific areas, as well as reporting monthly back to the board.
Executive officers include the chief operational manager, the chief scientific officer, the head of R&D, fundraising officer and valorization officer.
The board may appoint other officers for corporate-wide functions – this includes Conference Planning, Legal Affairs, Marketing and Publicity, among others. The board delegates the authority to set and execute corporate policy within the officer’s specific area of responsibility.
The chief operational officer is in charge of the infrastructure and hardware that keeps Artemis running. Since our infrastructure (websites, mailing lists, source code control, database, ordering, etc.) is a shared resource for all projects at Artemis, it is managed centrally.
PMC is in charge of writing grants and managing the running projects. External funding is the primary source of money for various projects and programs. This funding allows Artemis to carry out its objectives more adequately and to expand and enhance the variety of opportunities available in Artemis. The policies executed by Artemis should establish responsibility and accountability during the grant program.
Grants for approved research and sponsored projects are the fiscal responsibility of Artemis and are awarded to Artemis. Artemis holds the project director and principal investigator individually responsible for the proper management of the grant and for meeting the objectives of the grant. Artemis will ultimately be held responsible for the overall administration of funded projects. Therefore, all funds related to grants, regardless of source, shall be administered as research funds in accordance with Dutch law, European policies and Artemis policies and procedures.
FINANCIALS AND STRATEGIC PLAN
The foundation possesses an ANBI-status (Public Benefit Organisation) to receive donations. The ANBI-status has several tax benefits.
- An ANBI does not pay inheritance tax or gift tax for inheritances and donations that the institution uses for public interest.
- If an ANBI makes donations for public interest, then the recipient does not need to pay gift tax.
- An ANBI is eligible for energy tax refund.
- Volunteers working for an ANBI are therewith providing a donation under particular conditions.
- Donors of an ANBI are allowed to deduct their donations from the income tax or corporate tax.
To be eligible for tax deduction of periodical donations, the donor and ANBI must enter the donation into an agreement.
We are living in a rapidly changing world with an increased frequency of emerging viral infections in animals and humans. More attention needs to be given to understanding the drivers of emergence of infectious diseases, which may allow the transition to a more sustainable society. It is this daunting task that lies at the foundation of our strategy and thus for the future course of Artemis. The goals of the Strategic Plan will be realized step-by-step by identifying priority areas for each year of the Plan. In the future, we will continue to build on our strengths in scientific excellence to improve the health and wellbeing of society and to boost innovation and economic growth. Our strong commitment to supporting high quality fundamental discovery research will remain at the heart of our strategy.
Over the next five years Artemis aims to support excellent discovery science across the fields of virology, immunology to virus infections, vaccinology, and nanomedicine and strengthen partnerships to accelerate the pace of improvements in health and wealth.
We will achieve this through:
- Strategic aim one:
Picking research that delivers: setting research priorities, which are most likely to deliver improved health outcomes.
- Strategic aim two:
Research to people: bringing the benefits of excellent research to all sections of society, rich and poor.
- Strategic aim three:
Supporting scientists: sustaining a robust and flourishing environment for world-class researchers.
Our strategy is to support excellent research in areas that pose an enormous challenge to the health of individuals and animals in the Netherlands and the world. While focusing on problems with significant impact, we also support excellent science in areas that would be otherwise neglected or under-funded. In essence, Artemis supports viro-immunological research across the whole spectrum from basic science to clinical studies.